Assessing the safety and effectiveness of Atogepant for migraine prevention in Korean adults
Post-marketing Surveillance Study to Evaluate the Safety and Effectiveness of Atogepant for the Prevention of Migraine in Korean Adult Patients
This study is testing how well and safely Atogepant works for preventing migraines in Korean adults who have chronic or episodic migraines.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | AbbVie Industry-sponsored |
| Locations | 4 sites (Hwaseong, Gyeonggido and 3 other locations) |
| Trial ID | NCT06603558 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the safety and effectiveness of Atogepant, an approved medication for migraine prevention, in Korean adults suffering from chronic or episodic migraines. Approximately 3000 participants will be enrolled, all of whom will be prescribed Atogepant by their healthcare providers. Participants will be monitored for up to 12 weeks during routine clinical visits, with no additional burden placed on them. The study aims to gather real-world data on the drug's performance in a clinical setting.
Who should consider this trial
Good fit: Ideal candidates for this study are Korean adults diagnosed with chronic or episodic migraines who are prescribed Atogepant.
Not a fit: Patients who have contraindications to Atogepant or are currently involved in other clinical research may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness of Atogepant for preventing migraines in the Korean population.
How similar studies have performed: Other studies have shown positive results with Atogepant for migraine prevention, indicating that this approach is supported by prior evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants with migraine suitable for the treatment with atogepant according to the latest approved local label. * Participants prescribed atogepant in accordance with the approved local label. Exclusion Criteria: * Participants with any contraindication to atogepant as listed on the latest approved local label. * Participants currently participating in another clinical research except observational study.
Where this trial is running
Hwaseong, Gyeonggido and 3 other locations
- Hallym University Dongtan Sacred Heart Hospital /ID# 273581 — Hwaseong, Gyeonggido, South Korea (Recruiting)
- Seoul National University Hospital /ID# 271892 — Seoul, Seoul Teugbyeolsi, South Korea (Recruiting)
- Kangbuk Samsung Hospital /ID# 271893 — Seoul, Seoul Teugbyeolsi, South Korea (Recruiting)
- Yonsei University Health System Severance Hospital /ID# 272639 — Seoul, Seoul Teugbyeolsi, South Korea (Recruiting)
Study contacts
- Study coordinator: Celine Im
- Email: celine.im@abbvie.com
- Phone: +82-10-2230-3629
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.